Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Tunisia: These 9 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Tunisia: These 9 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Tunisia Patent SN08495
Patent Title: POLYMORPHS OF N-HYDROXY-3-[4-[[[2-(2- METHYL-IH-INDOL-3-YL) ETHYL] MINO] METHYL] PHENYL] -2E-2-PROPENAMIDE

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Tunisia Patent SN08460
Patent Title: 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Tunisia Patent SN08538

EXFORGE HCT is a drug marketed by Novartis.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Tunisia Patent 2,009,000,225
Patent Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE KINASE INHIBITORS

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,317
Patent Title: SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch?

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,347

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,447
Patent Title: AN EXTENTED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Tunisia Patent 2,009,000,514
Patent Title: SALTS OF THE JANUS KINASE INHIBITOR (R) -3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 11, 2027
Generic Entry Controlled by: Tunisia Patent SN07264
Patent Title: ORGANIC COMPOUNDS

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Last updated: January 5, 2026

Executive Summary

Tunisia’s pharmaceutical industry operates within a growing healthcare landscape driven by demographic shifts, increasing disease burden, and a focus on local manufacturing. The market features a mix of imported branded drugs and a nascent but expanding generic segment. Regulatory frameworks are evolving to favor local production and biosimilar development, presenting significant opportunities alongside notable challenges.

This analysis offers a comprehensive overview of Tunisia’s branded and generic drug markets, including market size, key players, regulatory environment, and strategic considerations for stakeholders.

Market Overview: Size, Trends, and Composition

Market Size and Growth Forecast

Total Pharmaceutical Market (2022): Estimated at $430 million [1].
Growth Rate: Compound annual growth rate (CAGR) projected at 4.2% (2023–2027), driven by increasing healthcare demands and government reforms.
Import Dependence: Approximately 80% of pharmaceuticals are imported, mainly from Europe, India, and China [2].
Local Manufacturing: Accounts for roughly 20% of consumption**, with government initiatives promoting local production.

Market Segmentation: Branded vs. Generic Drugs

Segment	Estimated Market Share	Characteristics
Branded Pharmaceuticals	~65%	Mostly patented innovations, higher retail prices
Generics	~35%	Off-patent, lower-cost alternatives, growing acceptance

Key Market Drivers

Rising healthcare expenditure.
Population aging and chronic disease prevalence.
Government policies promoting local manufacturing.
Increasing access to healthcare facilities.

Regulatory Environment: Framework, Opportunities, and Barriers

Current Regulatory Framework

Tunisia’s pharmaceutical regulations are governed by the Ministry of Health (MoH) and Tunisian Pharmaceutical Control Office (OCT). The key legal references include:

Pharmaceutical Law No. 97-32 (1997)
Decree No. 2003-1744 (2003)
Regulatory pathways for registration, manufacturing, importation, and quality assurance are aligned with WHO standards but are undergoing reform to align more closely with international best practices.

Regulatory Approval Process

Step	Description	Duration	Notes
Application Submission	Dossier review by OCT	3–6 months	Requires comprehensive documentation
Bioequivalence Testing	For generics	Variable	Not mandatory yet but increasingly encouraged
Inspection & Release	Factory inspections	1–3 months	For local manufacturers and importers

No centralized regulatory agency for biosimilars exists yet, but the government plans to establish one by 2025 [3].

Opportunities in Regulatory Modernization

Fast-Track Approvals: Implement accelerated pathways for essential medicines.
Local Manufacturer Support: Waivers or expedited processes for local producers.
Harmonization: Align with regional standards (African Medicines Agency) to facilitate exports.

Regulatory Challenges

Lengthy approval timelines, delaying product launches.
Limited bioequivalence capacity for generics, affecting market entry.
Insufficient local expertise in specialized sectors like biosimilars.
Stringent quality standards for imports, increasing costs.

Market Entry Strategies: Opportunities and Challenges for Stakeholders

For Multinational Branded Drugs

Opportunities	Challenges
Established presence in Africa	Stringent registration process
High demand for innovative therapies	Competition from local generics
Potential for public-private partnerships (PPPs)	Price controls

For Domestic and Generic Manufacturers

Opportunities	Challenges
Growing acceptance of generics	Limited regulatory transparency
Opportunities under government policies promoting local production	Need for quality investments
Potential export markets (regional)	Capacity constraints

Key Regulations Favoring Local Manufacturing

Government incentives: tax breaks, import duties exemptions.
Local content requirements: mandated minimum production local content.
Price control policies: to keep medications affordable.

Comparison: Tunisia vs. Regional Markets

Aspect	Tunisia	Egypt	South Africa
Market Size (2022)	$430 million	$2.2 billion	$1.1 billion
Regulatory Stringency	Moderate	Moderate–high	High
Local Manufacturing Presence	Small but growing	Significant	Established
Generic Market Penetration	35%	40–50%	45–55%
Investment Climate	Emerging	Improving	Mature

Note: Tunisia’s market remains less mature relative to Egypt and South Africa but exhibits promising growth potential.

Opportunities in Biosimilars and Innovative Drugs

Biosimilars: Regulatory absence but planned establishment by 2025 offers opportunities.
Innovative Drugs: Adoption driven by private sector and specialized hospitals.
Collaborations: Partnerships with European and Asian biotech firms can facilitate market entry.

Key Challenges to Consider

Challenge	Mitigation Strategies
Regulatory delays and uncertainty	Engage early with OCT; monitor policy updates
Limited manufacturing capacity	Invest in local facilities; leverage government incentives
Pricing pressures	Develop differentiated value propositions
Insufficient local R&D	Partner with universities; seek government grants
Market fragmentation	Focus on niche therapeutic areas

Policy and Strategic Recommendations

Stakeholder Engagement: Close dialogue with MoH and OCT to influence regulatory reforms.
Local Production Investment: Capitalize on government incentives and local market growth.
Quality & Compliance: Prioritize adherence to WHO standards to facilitate regional exports.
Bioequivalence Capabilities: Develop in-house testing for generics to reduce approval time.
Regional Expansion: Evaluate export potentials within Africa, leveraging regional trade agreements.

Key Takeaways

Market Growth: Tunisia’s pharmaceutical market is projected to grow at approximately 4.2%, with generics constituting a significant and expanding segment.
Regulatory Environment: Progressive but requires modernization to attract more investment, especially in biosimilars and innovative medicines.
Opportunities: Local manufacturing, biosimilar development, private sector expansion, and regional exports.
Challenges: Regulatory delays, capacity constraints, price controls, and market fragmentation.
Strategic Focus: Stakeholder engagement, investment in quality infrastructure, and partnerships are critical to capitalizing on market opportunities.

FAQs

Q1: What are the main regulatory hurdles for pharmaceutical companies entering Tunisia?
A: Lengthy approval timelines, limited bioequivalence testing capacity, and evolving standards pose challenges for market entry and speed to market.

Q2: How does Tunisia’s generic drug market compare to neighboring countries?
A: Tunisia’s generic penetration (~35%) is modest but expected to grow; its regulatory framework is less mature than Egypt but offers opportunities, especially with upcoming reforms.

Q3: Are biosimilars a viable opportunity in Tunisia?
A: Yes; with planned regulatory frameworks arriving by 2025, biosimilars hold potential, especially given regional demand for affordable biologic therapies.

Q4: What incentives does the Tunisian government offer to local pharmaceutical manufacturers?
A: Tax incentives, import duty exemptions, local content requirements, and support for capacity expansion to promote indigenous production.

Q5: How can foreign companies mitigate risks related to market access in Tunisia?
A: Engage in early regulatory dialogue, partner with local firms, invest in quality infrastructure, and align products with local policies focusing on affordability and access.

References

[1] Tunisian Ministry of Health, 2022 Data.
[2] IQVIA Tunisia Pharmaceutical Market Reports, 2022.
[3] World Health Organization, Regional Office for Africa, 2023.